A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
Status:
Completed
Trial end date:
2016-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the optimal dose of trabectedin for Chinese patients
with locally advanced or metastatic L-sarcoma (liposarcoma or leiomyosarcoma) who were
previously treated (in any order) with at least an anthracycline and ifosfamide containing
regimen, or an anthracycline containing regimen and 1 additional cytotoxic chemotherapy
regimen (Part 1) and to evaluate whether the overall survival (OS) of the trabectedin group
is superior to dacarbazine group (Part 2).